Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
R. S. Baric, A. Schaefer, S. R. Leist, L. Gralinski, D. Martinez, E. S. Winkler, K. Okuda, P. E. Hawkins, K. L. Gully, R. L. Graham, T. D. Scobey, T. A. Bell, P. Hock, G. D. Shaw, J. F. Loome, , M. T. Ferris
The paper identifies a multitrait locus on mouse Chromosome 9 that regulates SARS-CoV, SARS-CoV-2, and bat sarbecovirus disease severity, with candidate genes CCR9 and CXCR6.
bioRxiv · Jun 1, 2022Microbiology
L. Tostanoski, L. Gralinski, D. Martinez, A. Schaefer, S. Mahrokhian, Z. Li, F. Nampanya, H. Wan, J. Yu, A. Chang, J. Liu, K. McMahan, K. Dinnon, S. R. Leist, R. S. Baric, D. H. Barouch
This study evaluates the protective efficacy of rhesus adenovirus serotype 52 vaccines against a mouse-adapted SARS-CoV-2 strain, showing robust antibody responses and protection against viral replication and disease.
bioRxiv · Jun 14, 2021Microbiology
J. Graham, J. Swarts, S. R. Leist, A. Schafer, V. D. Menachery, L. Gralinski, S. Jeng, D. R. Miller, M. Mooney, S. McWeeney, M. T. Ferris, F. Pardo-Manuel de Villena, M. T. Heise, R. S. Baric, J. M. Lund
The paper shows that baseline T cell immune signatures in mice predict virologic and disease outcomes upon SARS-CoV infection.
bioRxiv · Sep 21, 2020Immunology
A. C. Walls, B. Fiala, A. Schaefer, S. Wrenn, M. N. Pham, M. Murphy, L. V. Tse, L. Shehata, M. A. O'Connor, C. Chen, M. J. Navarro, M. C. Miranda, D. Pettie, R. Ravichandran, J. C. Kraft, , N. P. King
This study designs SARS-CoV-2 nanoparticle vaccines that induce strong neutralizing antibodies in mice, with higher titers and lower doses than existing trimer vaccines.
bioRxiv · Aug 11, 2020Immunology
S. J. Zost, P. Gilchuk, R. Chen, J. B. Case, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, E. C. Chen, E. Binshtein, S. Shrihari, M. A. Ostrowski, H. Y. Chu, J. E. Didier, , J. E. Crowe
This study isolates and profiles human monoclonal antibodies against SARS-CoV-2 spike protein, identifying neutralizing antibodies targeting the receptor-binding domain.
bioRxiv · May 12, 2020Immunology
J. A. Plante, K. Plante, L. Gralinski, A. Beall, M. T. Ferris, D. Bottomly, R. R. Green, S. McWeeney, M. T. Heise, R. S. Baric, V. D. Menachery
This study identifies Muc4 as a protective factor in female mice against SARS-CoV pathogenesis, showing sex-specific effects without altering viral titers.
bioRxiv · Feb 19, 2020 · PreprintMicrobiology
V. D. Menachery, K. Dinnon, B. Yount, E. T. McAnarney, L. Gralinski, A. E. Hale, R. Graham, T. D. Scobey, S. J. Anthony, L. Wang, B. S. Graham, S. H. Randell, W. I. Lipkin, R. S. Baric
This study shows that proteolytic cleavage, not receptor binding, is the main barrier for two MERS-like bat coronaviruses to infect human cells, and that trypsin treatment can overcome this barrier.
bioRxiv · Sep 16, 2019Microbiology
V. D. Menachery, L. Gralinski, H. D. Mitchell, K. Dinnon, S. R. Leist, B. Yount, E. T. McAnarney, R. Graham, K. M. Waters, R. S. Baric
This study shows combining NSP16 mutation with other attenuating mutations creates a safe and effective live-attenuated coronavirus vaccine that works in aged mice and against heterologous challenges.
bioRxiv · Apr 28, 2018Microbiology